Hartmann A, Holdaas H, Fauchald P, Nordal K P, Berg K J, Talseth T, Leivestad T, Brekke I B, Flatmark A
Department of Internal Medicine, National Hospital, Oslo, Norway.
Transpl Int. 1992 Mar;5(1):15-8. doi: 10.1007/BF00337183.
At our center 62 renal transplantations (31 living donor and 31 cadaveric donor grafts) have been performed in 58 patients with amyloid renal disease since 1974. The amyloidosis was secondary to rheumatic disease in 74% of the patients. Predialytic transplantation was performed in 28% of the patients. Mean follow-up time was 5.1 years (0.3-14.5 years). One-year actuarial patient survival was 79%, decreasing to 65% after 5 years. First graft survival was 74% at 1 year and 62% at 5 years. Patient death with a functioning graft caused 16 out of 25 graft losses. Infections caused 11 out of 18 deaths (61%), more than half of them within 3 months. Renal transplant amyloid was diagnosed in about 10% of the cases (6/62); however, only about 3% of the grafts (2/62) were lost. These long-term results encourage transplantation in amyloid renal end-stage disease.
自1974年以来，我们中心已为58例淀粉样肾病患者进行了62例肾移植手术（31例活体供肾和31例尸体供肾移植）。74%的患者淀粉样变性继发于风湿性疾病。28%的患者在透析前进行了移植。平均随访时间为5.1年（0.3 - 14.5年）。1年实际患者生存率为79%，5年后降至65%。首次移植1年生存率为74%，5年生存率为62%。25例移植肾失功中有16例是由于患者带功死亡。感染导致18例死亡中的11例（61%），其中一半以上发生在3个月内。约10%的病例（6/62）诊断为移植肾淀粉样变；然而，仅约3%的移植肾（2/62）失功。这些长期结果鼓励对淀粉样肾病终末期疾病进行移植。
